"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
TRACRIUM (atracurium besylate) is a nondepolarizing skeletal muscle relaxant. Nondepolarizing agents antagonize the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. This antagonism is inhibited, and neuromuscular block reversed, by acetylcholinesterase inhibitors such as neostigmine, edrophonium, and pyridostigmine.
The duration of neuromuscular block produced by TRACRIUM (atracurium besylate) is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of TRACRIUM (atracurium besylate) .
The ED95 (dose required to produce 95% suppression of the muscle twitch response with balanced anesthesia) has averaged 0.23 mg/kg (0.11 to 0.26 mg/kg in various studies). An initial dose of TRACRIUM (atracurium besylate) of 0.4 to 0.5 mg/kg generally produces maximum neuromuscular block within 3 to 5 minutes of injection, with good or excellent intubation conditions within 2 to 2.5 minutes in most patients. Recovery from neuromuscular block (under balanced anesthesia) can be expected to begin approximately 20 to 35 minutes after injection. Under balanced anesthesia, recovery to 25% of control is achieved approximately 35 to 45 minutes after injection, and recovery is usually 95% complete approximately 60 to 70 minutes after injection. The neuromuscular blocking action of TRACRIUM (atracurium besylate) is enhanced in the presence of potent inhalation anesthetics. Isoflurane and enflurane increase the potency of TRACRIUM (atracurium besylate) and prolong neuromuscular block by approximately 35%; however, halothane†s potentiating effect (approximately 20%) is marginal (see DOSAGE AND ADMINISTRATION).
Repeated administration of maintenance doses of TRACRIUM (atracurium besylate) has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results. After an initial dose of 0.4 to 0.5 mg/kg under balanced anesthesia, the first maintenance dose (suggested maintenance dose is 0.08 to 0.10 mg/kg) is generally required within 20 to 45 minutes, and subsequent maintenance doses are usually required at approximately 15- to 25-minute intervals.
Once recovery from the neuromuscular blocking effects of TRACRIUM (atracurium besylate) begins, it proceeds more rapidly than recovery from d-tubocurarine, metocurine, and pancuronium. Regardless of the dose of TRACRIUM (atracurium besylate) , the time from start of recovery (from complete block) to complete (95%) recovery is approximately 30 minutes under balanced anesthesia, and approximately 40 minutes under halothane, enflurane, or isoflurane. Repeated doses have no cumulative effect on recovery rate.
Reversal of neuromuscular block produced by TRACRIUM (atracurium besylate) can be achieved with an anticholinesterase agent such as neostigmine, edrophonium, or pyridostigmine, in conjunction with an anticholinergic agent such as atropine or glycopyrrolate. Under balanced anesthesia, reversal can usually be attempted approximately 20 to 35 minutes after an initial dose of TRACRIUM (atracurium besylate) of 0.4 to 0.5 mg/kg, or approximately 10 to 30 minutes after a 0.08- to 0.10-mg/kg maintenance dose, when recovery of muscle twitch has started. Complete reversal is usually attained within 8 to 10 minutes of the administration of reversing agents. Rare instances of breathing difficulties, possibly related to incomplete reversal, have been reported following attempted pharmacologic antagonism of neuromuscular block induced by TRACRIUM (atracurium besylate) . As with other agents in this class, the tendency for residual neuromuscular block is increased if reversal is attempted at deep levels of block or if inadequate doses of reversal agents are employed.
The pharmacokinetics of TRACRIUM (atracurium besylate) in humans are essentially linear within the 0.3- to 0.6-mg/kg dose range. The elimination half-life is approximately 20 minutes. THE DURATION OF NEUROMUSCULAR BLOCK PRODUCED BY TRACRIUM (atracurium besylate) DOES NOT CORRELATE WITH PLASMA PSEUDOCHOLINESTERASE LEVELS AND IS NOT ALTERED BY THE ABSENCE OF RENAL FUNCTION. This is consistent with the results of in vitro studies which have shown that TRACRIUM (atracurium besylate) is inactivated in plasma via two nonoxidative pathways: ester hydrolysis, catalyzed by nonspecific esterases; and Hofmann elimination, a nonenzymatic chemical process which occurs at physiological pH. Some placental transfer occurs in humans.
Radiolabel studies demonstrated that TRACRIUM (atracurium besylate) undergoes extensive degradation in cats, and that neither kidney nor liver plays a major role in its elimination. Biliary and urinary excretion were the major routes of excretion of radioactivity (totaling >90% of the labeled dose within 7 hours of dosing), of which TRACRIUM (atracurium besylate) represented only a minor fraction. The metabolites in bile and urine were similar, including products of Hofmann elimination and ester hydrolysis.
Elderly patients may have slightly altered pharmacokinetic parameters compared to younger patients, with a slightly decreased total plasma clearance which is offset by a corresponding increase in volume of distribution. The net effect is that there has been no significant difference in clinical duration and recovery from neuromuscular block observed between elderly and younger patients receiving TRACRIUM (atracurium besylate) .
TRACRIUM (atracurium besylate) is a less potent histamine releaser than d-tubocurarine or metocurine. Histamine release is minimal with initial doses of TRACRIUM (atracurium besylate) up to 0.5 mg/kg, and hemodynamic changes are minimal within the recommended dose range. A moderate histamine release and significant falls in blood pressure have been seen following 0.6 mg/kg of TRACRIUM (atracurium besylate) . The histamine and hemodynamic responses were poorly correlated. The effects were generally short-lived and manageable, but the possibility of substantial histamine release in sensitive individuals or in patients in whom substantial histamine release would be especially hazardous (e.g., patients with significant cardiovascular disease) must be considered.
It is not known whether the prior use of other nondepolarizing neuromuscular blocking agents has any effect on the activity of TRACRIUM (atracurium besylate) . The prior use of succinylcholine decreases by approximately 2 to 3 minutes the time to maximum block induced by TRACRIUM (atracurium besylate) , and may increase the depth of block. TRACRIUM (atracurium besylate) should be administered only after a patient recovers from succinylcholine-induced neuromuscular block.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Tracrium Information
- Tracrium Drug Interactions Center: atracurium iv
- Tracrium Side Effects Center
- Tracrium FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Find out what women really need.